CP1262561-1 ICD Registry Background – Current – Next Steps.

Slides:



Advertisements
Similar presentations
Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Advertisements

Heart Rhythm 2008 San Francisco May 15, 2008 Stephen Hammill, MD Heart Rhythm 2008 San Francisco May 15, 2008 Stephen Hammill, MD CP Using the.
Implantable Cardioverter Defibrillator: Overview of the NCDR Data Methodology Christie Lang, RN, MSN Associate Director, ICD Registry American College.
Medicaid Division of Medicaid and Long-Term Care Department of Health and Human Services Managed Long-Term Services and Supports.
American College of Cardiology Transforming Science into Quality Care Alfred A. Bove, MD, PhD, FACC.
MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J. Moss, MD for the MADIT-RIT Executive Committee AHA Late Breaking Trials November.
Factors Influencing the Use of Higher-Tech/Higher Cost Implantable Cardioverter-Defibrillators: Data from the NCDR ® ICD Registry TM Rachel Lampert, MD,
Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral.
Gillian D Sanders Ph.D.Lurdes Y Inoue Ph.D. Associate Professor of MedicineAssociate Professor of Biostatistics Duke UniversityUniversity of Washington.
Truven Health Analytics State Exchanges - Data Collection & Analysis April 2014.
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Documentation for Acute Care
Longitudinal Study of Implantable Cardioverter Defibrillators (ICDs) AHRQ Annual Meeting - September 21, 2011 Robert Greenlee, PhD, MPH Marshfield Clinic.
Selection of Data Sources for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
MaineHealth ACO in Context W 5 Who? What? Why? When? HoW? 1.
Making Large Data Sets Work for You Advantages and Challenges Lesley H Curtis Soko Setoguchi Bradley G Hammill.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
QI ACTION Registry-Get With The Guidelines The Mission Lifeline Data Solution Kathleen O’Neill, MHA Senior Director, Quality Initiatives IL & SD American.
Bidders’ Conference Convened by Dirigo Health Agency June 18, 2012 Solicitation to Select Designated Survey Vendors.
Outcomes of screening mammography among women aged 40 to 43 Institute for Clinical Evaluative Sciences Toronto, Canada (2006)
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
American College of Cardiology Transforming Science into Quality Care.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.
What Did I Work on in Washington? John Glaser April 16, 2010.
Reducing Re-hospitalizations: The ICU Survivors Follow-Up Care Program Shirley F. Jones, MD Scott & White Healthcare/Texas A&M Health Science Center.
Registry Data Collection in Pediatric VADs: Challenges and Opportunities INTERMACS Eighth Annual Meeting May 5, 2014 David Rosenthal, MD Stanford Children’s.
Special Needs Plans Models of Care SNP Educational Conference Baltimore, MD January 13, 2014 Susan Radke, MCAG Division of Policy, Analysis, and Planning.
California Stroke Registry Right Care Initiative Meeting August 13, 2012.
ACTION Registry. Objectives of the NCDR Registries Provide data standardization Provide data that is –Relevant, Credible, Timely, Actionable Present real.
Managed Care. In the broadest terms, Kongstvedt (1997) describes managed care as a system of healthcare delivery that tries to manage the cost of healthcare,
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
THE HIT ADOPTIONINITIATIVE The George Washington University School of Public Health and Health Services The Institute for Health Policy at MGH/Partners.
Acute Lead Dislodgements in NCDR ® ICD Registry™ Patients Alan Cheng, MD, Yongfei Wang, MS, Jeptha P. Curtis, MD, Paul D. Varosy, MD Johns Hopkins University.
1 The Role of Medicare National Coverage in the Regulatory Process Steve Phurrough MD, MPA Director, Coverage and Analysis Group Centers for Medicare and.
Industry Prospective Robin Bostic, Thoratec VP Health Policy and Health Economics INTERMACS Industry Sub-Committee Representative Our Future.
CP CathPCI Registry 10 Years and We Keep Going.
Melissa McCarey, MPH Jefferson Clinical Research Institute (JCRI) Clinicaltrials.gov: What is it? What do I need to know?
Patient Protection and Affordable Care Act The Greens: Elijah, Amber, Kayla, Patrick.
NCDR Registry Statistics End of 4th Quarter 2011 Registry # of Participants # of Patient Records # of Manuscripts/ Abstracts ACTION Registry®- GWTG TM.
Unit 9: Evaluating a Public Health Surveillance System #1-9-1.
CP CARE Registry Insights to the Future.
The Hospital CAHPS Program Presented by Maureen Parrish.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
11 Kansas Heart & Stroke Collaborative September 22 and 23, 2014.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Evidence in the Coverage Process: An Evolving Paradigm Kevin Schulman, M.D. Director, Center for Clinical and Genetic Economics Duke University Medical.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
22 nd Annual Rural Health Policy Institute Deputy Administrator, HRSA Marcia K. Brand, PhD January 24, 2011.
1 Can Quality Improvement Activities Encourage Physicians to Adopt Best Practices in the Delivery of Care? Evidence from a Quality Improvement Project.
Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.
Intersecting roles CMS and FDA – implications for pharmaceutical and device industries Peter B. Bach, MD, MAPP Senior Adviser, Office of the Administrator.
Washington Update PACT Medical Device Group March 7, 2013 Mark Leahey
Clinicaltrials.gov Update
MUHC Innovation Model.
STEMI Systems of Care – Update on Mission: Lifeline:
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
Washington Update PACT Medical Device Group March 7, 2013 Mark Leahey
Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials.gov Content downloaded: September 2012.
ICD Registry Jan/Feb 2010 Update
Comparing Options for Management:PAtient-centered REsults for Uterine Fibroids Evan R. Myers, MD, MPH Department of Obstetrics & Gynecology and Duke Clinical.
Optum’s Role in Mycare Ohio
ICD Registry November 2009 Update
Megan Eguchi, MPh Sana karam, md, phd
Presentation transcript:

CP ICD Registry Background – Current – Next Steps

Highlights to Date 1,438 hospitals >135,000 implants – 55% are primary prevention CMS patients 90% of implants from hospitals entering all patients (1° and 2° prevention, all ages) Longitudinal registry developed Research and publications in progress

Developing the Baseline Registry 9/28/04: CMS published proposed NCD –Following SCD-HeFT release –National data base proposed –HRS asked to chair the Working Group to develop the registry 11/22/04: Working Group recommendations sent to CMS –Purpose of the registry –Patients to be enrolled –Patient and device data elements to be collected –Defining providers as competent and qualified to implant ICDs

Developing the Baseline Registry 1/27/05: CMS published final NCD –Expanded ICD indications –CED process described –Data collection using QNet Temporary data collection tool

What does CMS hope to gain from the Registry? CMS’s goal is to determine whether primary prevention ICD’s are appropriate for the Medicare beneficiaries who meet the clinical conditions identified in the agencies NCD of 1/27/05. Coverage with evidence development (CED)

Coverage with evidence development “Develop evidence on what works best in clinical practice... explicit, rapid, evidence based on a process that is predictable with transparency... improve the knowledge base by which patients and providers can make better treatment decisions.” Mark McClellan Administrator, CMS 2/14/05 Conference call

Developing the Baseline Registry 1/27/05: CMS published final NCD –Expanded indications –CED process described –Data collection using QNet Temporary data collection tool 3/05: HRS asked to reconvene the Working Group –Define questions that should be answered –Define the core characteristics of a national clinical registry 5/19/05: Recommendations sent to CMS

Developing the Baseline Registry 10/27/05: CMS selected the ICD Registry developed by ACC and HRS based on the NCDR 4/1/06: All data submitted to ICD Registry; QNet phased out –Hospitals encouraged to submit data on all patients –SCD-HeFT patients yrs –Medicare patients yrs 4/07: Quarterly benchmarking reports sent to hospitals –DQR process –Random auditing

Developing the Longitudinal Registry

“It is particularly important that these factors (ICD firing data and survival) be determined in the actual population receiving ICDs, who are older and present more comorbidities than represented in the trial populations. Fortunately, these key factors will be tracked in the ICD Registry” Lynne Warner Stevenson, MD Circulation. 2006;114:101

Developing the Longitudinal Registry 3/8/06: HRS asked to reconvene the Working Group –Working Group expanded –Refine the CED questions (group B questions) –Develop the Longitudinal Registry

National ICD Registry Working Group HRS, Chair HFSA Medtronic Guidant BCBS United HealthCare Am Hlth Ins Plans FDA CMS ACC AHA Biotronik St. Jude NCDR Aetna AHRQ Am. Hosp. Assoc. At large members

Longitudinal Registry Task Force #1: Refine the Group B Questions Members –Lynne Warner Stevenson, Chair –Stephen Hammill (HRS) –Gillian Sanders (Duke) –Eric Fain (St. Jude) –Neil Jenson (Health Partners) –Marcel Salive (CMS) –Joel Harder (HRS)

Longitudinal Registry Task Force #1: Refine the Group B Questions NCD –B1: Do patient outcomes differ for patients with ejection fractions above and below 30%? Final –B1: What are the rates of device therapies during the first 3 years after implantation for patients with LVEF 31-35% and patients with LVEF  30%? –These rates will be interpreted in context of the absolute survival rates during the same period.

Longitudinal Registry Task Force #1: Refine the Group B Questions NCD –B2: Do patient outcomes differ for patients with nonischemic CHF based on time from diagnosis? Final –B2: What are the rates of device therapies during the first 3 years for patients with a diagnosis of nonischemic cardiomyopathy for <9 months and patients with diagnosis  9 months?

Longitudinal Registry Task Force #1: Refine the Group B Questions NCD –B3: Do patient outcomes differ for patients with Class IV CHF? Final –B3: What are the rates of device therapies during the first 3 years for patients who are NYHA Class IV at the time of implantation of a CRT-D device and for patients who are Class III at the time of CRT-D placement?

Longitudinal Registry Task Force #2: Develop the Methodology to Obtain Device Therapy Data Members –Peter Bach, Chair –Stephen Hammill (HRS) –Alan Kadish (Northwestern) –Steve Pearson (AHIP) –Mark Grant (BCBS) –Bob Thompson (Medtronic) –Marcel Salive (CMS) –Kristi Mitchell (NCDR) –Jeptha Curtis (Yale) –Harlan Krumholz (Yale) –Joel Harder (HRS)

Longitudinal Registry Study Design Yale CORE – Data analytic centerYale CORE – Data analytic center NCDR – Data collection and coordination centerNCDR – Data collection and coordination center HRS – Physician recruitment and oversightHRS – Physician recruitment and oversight Eligible patientsEligible patients –CMS beneficiaries receiving a primary prevention ICD

Longitudinal Registry Study Design Primary endpointPrimary endpoint –First delivery of an appropriate ICD therapy (shock, ATP) Secondary endpointSecondary endpoint –Survival probability at 3 and 5 years –Death from CV cause –Total # and rate of device therapies –Ratio of inappropriate to total device therapies

Longitudinal Registry Study Design 350 randomly selected implanting MDs350 randomly selected implanting MDs 3,500 patients followed 3 years for events and 5 years for survival3,500 patients followed 3 years for events and 5 years for survival –Based on 10% rate of appropriate therapy at 3 years (15% at 3 years in SCD-HeFT) Device therapy follow-upDevice therapy follow-up –Every 3 months for a minimum of 3 years –Adjudication process –Data combined with NDI and Medicare claims data

Longitudinal Registry Study Design Funding – $3.5 million neededFunding – $3.5 million needed –To date $1.5 million from industry$1.5 million from industry $1.0 million from AHIP$1.0 million from AHIP

Longitudinal Registry Study Design Interpretation of findingsInterpretation of findings –No threshold of device therapies or survival that would be pre-specified to be clinically meaningful –Results compared to the Baseline ICD Registry population to determine the appropriateness of ICD therapy in the 3 CED groups

Longitudinal Registry Patient Flow Follow-up form Follow-up visit ~q3 months for 3 years 5-year clinical follow-up CMS billing NDI 5-year clinical follow-up CMS billing NDI Notification of Coordinating Center Analytic Center Data Repository Adjudication Committee ICD implantation by participating MD Baseline ICD Registry

Next Steps Develop version 2.0 Research and publications Hospital responsible for Registry payment QI and P4P programs –CMS physician performance measures (PQRI) –Preferred Provider Status for United Health Care

Version 2.0 – Updating the Registry Redefine the registry purpose, goals and target audience Enhance the data collection forms and data collected Meet public policy Make the registry a performance reporting tool Post market surveillance (Sentinal Network) Coordinate with longitudinal data

Research and Publications Research requests are reviewed and prioritized by Research and Publication Subcommittee 19+ requests to date ICD-Registry provides financial support for data analysis Yale CORE assists with data analysis

Research and Publications Sample research proposals –How do the baseline characteristics of patients receiving ICD therapy in the general population (“real world”) compare with the characteristics of patients enrolled in randomized clinical trials of ICD therapy? –Are patient outcomes such as morbidity and mortality affected by patient baseline clinical characteristics such as ejection fraction, QRS duration, NYHA class, gender, age, and race?

Research and Publications Sample research proposals –What are the characteristics of the physicians implanting ICDs regarding training, experience, and volume; and how does this relate to implantation outcomes? –Does age, race, and sex distribution of patients undergoing ICD implantation differ among different regions of the country and different size of hospitals?

Why a Registry? Science tells us what we can do; Guidelines what we should do; and Registries what we are actually doing Science tells us what we can do; Guidelines what we should do; and Registries what we are actually doing. Lukas Kappenberger MD HRS ICD Policy Conference Washington DC, 9/16/05

For Additional Information NCDR Website: Service Center:(800) Monday –Friday, 8:00 am – 5:00 pm ET Fax:(202) Mailing address:2400 N Street NW Washington, DC 20037